JPWO2019152743A5 - - Google Patents

Info

Publication number

JPWO2019152743A5

JPWO2019152743A5 JP2020541784A JP2020541784A JPWO2019152743A5 JP WO2019152743 A5 JPWO2019152743 A5 JP WO2019152743A5 JP 2020541784 A JP2020541784 A JP 2020541784A JP 2020541784 A JP2020541784 A JP 2020541784A JP WO2019152743 A5 JPWO2019152743 A5 JP WO2019152743A5

Authority

JP

Japan

Prior art keywords

antigen

administration

antibody

days

day

Prior art date

2022-02-04

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 210000001744 T-lymphocyte Anatomy 0.000 claims description 183
• 239000000427 antigen Substances 0.000 claims description 171
• 102000036639 antigens Human genes 0.000 claims description 171
• 108091007433 antigens Proteins 0.000 claims description 171
• 239000012634 fragment Substances 0.000 claims description 141
• 238000002659 cell therapy Methods 0.000 claims description 110
• 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 90
• 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 54
• 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 54
• 210000004027 cell Anatomy 0.000 claims description 52
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 48
• 230000011664 signaling Effects 0.000 claims description 44
• 201000011510 cancer Diseases 0.000 claims description 42
• 210000004369 blood Anatomy 0.000 claims description 32
• 239000008280 blood Substances 0.000 claims description 32
• 230000001086 cytosolic effect Effects 0.000 claims description 19
• 239000000203 mixture Substances 0.000 claims description 19
• 238000002560 therapeutic procedure Methods 0.000 claims description 18
• 230000037361 pathway Effects 0.000 claims description 16
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 15
• 108090000623 proteins and genes Proteins 0.000 claims description 13
• 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 12
• 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 12
• 206010052015 cytokine release syndrome Diseases 0.000 claims description 12
• 102000004169 proteins and genes Human genes 0.000 claims description 12
• 108010074708 B7-H1 Antigen Proteins 0.000 claims description 11
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 11
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 10
• 206010028980 Neoplasm Diseases 0.000 claims description 10
• 229960004397 cyclophosphamide Drugs 0.000 claims description 10
• 210000004698 lymphocyte Anatomy 0.000 claims description 10
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 9
• 230000000903 blocking effect Effects 0.000 claims description 9
• 125000006850 spacer group Chemical group 0.000 claims description 9
• 231100000419 toxicity Toxicity 0.000 claims description 9
• 230000001988 toxicity Effects 0.000 claims description 9
• 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 8
• 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 8
• 229950009791 durvalumab Drugs 0.000 claims description 8
• 230000007774 longterm Effects 0.000 claims description 8
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 8
• 230000003442 weekly effect Effects 0.000 claims description 8
• 229960000390 fludarabine Drugs 0.000 claims description 7
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 7
• 201000003444 follicular lymphoma Diseases 0.000 claims description 7
• 230000000977 initiatory effect Effects 0.000 claims description 7
• 230000007135 neurotoxicity Effects 0.000 claims description 7
• 231100000228 neurotoxicity Toxicity 0.000 claims description 7
• 206010029350 Neurotoxicity Diseases 0.000 claims description 6
• 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 6
• 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 6
• 206010044221 Toxic encephalopathy Diseases 0.000 claims description 6
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
• 206010061818 Disease progression Diseases 0.000 claims description 4
• 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
• 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
• 230000005750 disease progression Effects 0.000 claims description 4
• 230000004068 intracellular signaling Effects 0.000 claims description 4
• 230000036210 malignancy Effects 0.000 claims description 4
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims description 3
• 102100021631 B-cell lymphoma 6 protein Human genes 0.000 claims description 3
• 108091012583 BCL2 Proteins 0.000 claims description 3
• 101000971234 Homo sapiens B-cell lymphoma 6 protein Proteins 0.000 claims description 3
• 208000021173 high grade B-cell lymphoma Diseases 0.000 claims description 3
• 239000003112 inhibitor Substances 0.000 claims description 3
• 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
• 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
• 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
• 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims description 2
• 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims description 2
• 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims description 2
• 230000000735 allogeneic effect Effects 0.000 claims description 2
• 229940045799 anthracyclines and related substance Drugs 0.000 claims description 2
• 229960003852 atezolizumab Drugs 0.000 claims description 2
• 229950002916 avelumab Drugs 0.000 claims description 2
• 229940121420 cemiplimab Drugs 0.000 claims description 2
• 239000003795 chemical substances by application Substances 0.000 claims description 2
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims description 2
• 229960003301 nivolumab Drugs 0.000 claims description 2
• 229960002621 pembrolizumab Drugs 0.000 claims description 2
• 210000004986 primary T-cell Anatomy 0.000 claims description 2
• 230000008707 rearrangement Effects 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims 46
• 229940079593 drug Drugs 0.000 claims 35
• 102000008096 B7-H1 Antigen Human genes 0.000 claims 5
• 125000003275 alpha amino acid group Chemical group 0.000 claims 3
• 231100000004 severe toxicity Toxicity 0.000 claims 3
• 239000008177 pharmaceutical agent Substances 0.000 claims 2
• 230000000139 costimulatory effect Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 141
• 150000001413 amino acids Chemical class 0.000 description 10
• 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 6
• 235000018102 proteins Nutrition 0.000 description 6
• 108010083359 Antigen Receptors Proteins 0.000 description 4
• 102000006306 Antigen Receptors Human genes 0.000 description 4
• 235000001014 amino acid Nutrition 0.000 description 4
• 108060003951 Immunoglobulin Proteins 0.000 description 3
• 102000018358 immunoglobulin Human genes 0.000 description 3
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
• 235000018417 cysteine Nutrition 0.000 description 2
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
• 108020003175 receptors Proteins 0.000 description 2
• 102000005962 receptors Human genes 0.000 description 2
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 210000001723 extracellular space Anatomy 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 108090000765 processed proteins & peptides Proteins 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1